Literature DB >> 19416912

The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway.

Mei Cui1, Radha Aras, Whitney V Christian, Phillip M Rappold, Mamata Hatwar, Joseph Panza, Vernice Jackson-Lewis, Jonathan A Javitch, Nazzareno Ballatori, Serge Przedborski, Kim Tieu.   

Abstract

Toxic organic cations can damage nigrostriatal dopaminergic pathways as seen in most parkinsonian syndromes and in some cases of illicit drug exposure. Here, we show that the organic cation transporter 3 (Oct3) is expressed in nondopaminergic cells adjacent to both the soma and terminals of midbrain dopaminergic neurons. We hypothesized that Oct3 contributes to the dopaminergic damage by bidirectionally regulating the local bioavailability of toxic species. Consistent with this view, Oct3 deletion and pharmacological inhibition hampers the release of the toxic organic cation 1-methyl-4-phenylpyridinium from astrocytes and protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration in mice. Furthermore, Oct3 deletion impairs the removal of the excess extracellular dopamine induced by methamphetamine and enhances striatal dopaminergic terminal damage caused by this psychostimulant. These results may have far-reaching implications for our understanding of the mechanism of cell death in a wide range of neurodegenerative diseases and may open new avenues for neuroprotective intervention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19416912      PMCID: PMC2683105          DOI: 10.1073/pnas.0900358106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice.

Authors:  A Giovanni; B A Sieber; R E Heikkila; P K Sonsalla
Journal:  J Pharmacol Exp Ther       Date:  1991-05       Impact factor: 4.030

2.  Neuroinflammation and Parkinson's disease.

Authors:  Serge Przedborski
Journal:  Handb Clin Neurol       Date:  2007

3.  Validity of a quantitative technique to study striatal dopaminergic neurodegeneration by in vivo microdialysis.

Authors:  M Santiago; A Machado; J Cano
Journal:  J Neurosci Methods       Date:  2001-07-30       Impact factor: 2.390

4.  Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives: structure-activity relationships.

Authors:  M C Scorza; C Carrau; R Silveira; G Zapata-Torres; B K Cassels; M Reyes-Parada
Journal:  Biochem Pharmacol       Date:  1997-12-15       Impact factor: 5.858

5.  Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice.

Authors:  Hong Guo; Liching Lai; Matthew E R Butchbach; Michael P Stockinger; Xiu Shan; Georgia A Bishop; Chien-liang Glenn Lin
Journal:  Hum Mol Genet       Date:  2003-08-05       Impact factor: 6.150

6.  Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress.

Authors:  J F Cubells; S Rayport; G Rajendran; D Sulzer
Journal:  J Neurosci       Date:  1994-04       Impact factor: 6.167

Review 7.  Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms.

Authors:  Jean Lud Cadet; Irina N Krasnova; Subramaniam Jayanthi; Johnalyn Lyles
Journal:  Neurotox Res       Date:  2007-04       Impact factor: 3.911

8.  Distribution of organic cation transporter 3, a corticosterone-sensitive monoamine transporter, in the rat brain.

Authors:  Paul J Gasser; Miles Orchinik; Ilangovan Raju; Christopher A Lowry
Journal:  J Comp Neurol       Date:  2009-02-01       Impact factor: 3.215

9.  The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity.

Authors:  David M Thomas; Dina M Francescutti-Verbeem; Donald M Kuhn
Journal:  J Neurochem       Date:  2007-12-06       Impact factor: 5.372

10.  Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease.

Authors:  Angelo C Lepore; Britta Rauck; Christine Dejea; Andrea C Pardo; Mahendra S Rao; Jeffrey D Rothstein; Nicholas J Maragakis
Journal:  Nat Neurosci       Date:  2008-10-19       Impact factor: 24.884

View more
  83 in total

1.  Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3.

Authors:  Phillip M Rappold; Mei Cui; Adrianne S Chesser; Jacqueline Tibbett; Jonathan C Grima; Lihua Duan; Namita Sen; Jonathan A Javitch; Kim Tieu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

Review 2.  Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Authors:  Sharawan Yadav; Anubhuti Dixit; Sonal Agrawal; Ashish Singh; Garima Srivastava; Anand Kumar Singh; Pramod Kumar Srivastava; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2012-06-27       Impact factor: 5.590

3.  Exercise protects against MPTP-induced neurotoxicity in mice.

Authors:  Kimberly M Gerecke; Yun Jiao; Amar Pani; Vishwajeeth Pagala; Richard J Smeyne
Journal:  Brain Res       Date:  2010-01-29       Impact factor: 3.252

Review 4.  Industrial toxicants and Parkinson's disease.

Authors:  W Michael Caudle; Thomas S Guillot; Carlos R Lazo; Gary W Miller
Journal:  Neurotoxicology       Date:  2012-01-30       Impact factor: 4.294

5.  Neurosteroid transport by the organic solute transporter OSTα-OSTβ.

Authors:  Fang Fang; Whitney V Christian; Sadie G Gorman; Mei Cui; Jiaoti Huang; Kim Tieu; Nazzareno Ballatori
Journal:  J Neurochem       Date:  2010-08-12       Impact factor: 5.372

6.  Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.

Authors:  O Sader-Mazbar; Y Loboda; M J Rabey; J P M Finberg
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

7.  Microglial exosomes facilitate α-synuclein transmission in Parkinson's disease.

Authors:  Min Guo; Jian Wang; Yanxin Zhao; Yiwei Feng; Sida Han; Qiang Dong; Mei Cui; Kim Tieu
Journal:  Brain       Date:  2020-05-01       Impact factor: 13.501

8.  Generation of Mitochondrial Toxin Rodent Models of Parkinson's Disease Using 6-OHDA , MPTP , and Rotenone.

Authors:  Hiroharu Maegawa; Hitoshi Niwa
Journal:  Methods Mol Biol       Date:  2021

Review 9.  Solvents and Parkinson disease: a systematic review of toxicological and epidemiological evidence.

Authors:  Edward A Lock; Jing Zhang; Harvey Checkoway
Journal:  Toxicol Appl Pharmacol       Date:  2012-12-07       Impact factor: 4.219

10.  Polyamine transport by the polyspecific organic cation transporters OCT1, OCT2, and OCT3.

Authors:  Monica Sala-Rabanal; Dan C Li; Gregory R Dake; Harley T Kurata; Mikhail Inyushin; Serguei N Skatchkov; Colin G Nichols
Journal:  Mol Pharm       Date:  2013-03-19       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.